Disease models: chemo, fibrosis & more

Beyond aging: where senolysis might actually land first

The most translatable use of FOXO4-DRI may not be anti-aging at all. Clearing the senescent cells that chemotherapy leaves behind, or that drive fibrosis, targets defined patient groups with bounded treatment windows, which is a far more tractable problem than slowing aging in healthy people.

This unit surveys the disease-model literature: chemotherapy recovery and lung fibrosis first, then the newer vascular and reproductive studies, which the later pages cover with their own sources.